AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7811016 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin (6 mg/kg once daily)
Number of subjects: 635
Study 7811016 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (1 g twice daily)
Number of subjects: 635
Study 7811016 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 635
Study 7811016 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 635
Study 3414546 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine hydrochloride
Number of subjects: 20
Study 30269638 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous ketamine
Number of subjects: 185
Study 30269638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 28523945 — intervention group
Group type: EXPERIMENTAL
Intervention: Menopause-related hormone therapy (MHT)
Number of subjects: 0
Study 28523945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25757964 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged PCI for non-infarction related artery (non-IRA) within 7-10 days after AMI (Group A)
Number of subjects: 428
Study 24311403 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition containing omega-3 polyunsaturated fatty acid, antioxidants, and glutamine
Number of subjects: 36
Study 24311403 — intervention group
Group type: COMPARATOR
Intervention: Standard care (fasting)
Number of subjects: 36
Study 24311403 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 36
Study 24311403 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid administration
Number of subjects: 36
Study 24311403 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal replacement therapy
Number of subjects: 36
Study 21205623 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium 20 µg kg(‐1), followed by four incremental 10 µg kg(‐1) doses, and the remainder of 100 µg kg(‐1)
Number of subjects: 2
Study 21205623 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 2
Study 18206256 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality assurance process in the ARTSCAN trial
Number of subjects: 734
Study 18206256 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of treatments
Number of subjects: 734
Study 18206256 — intervention group
Group type: EXPERIMENTAL
Intervention: Database of treatment parameters
Number of subjects: 734
Study 16861093 — intervention group
Group type: EXPERIMENTAL
Intervention: FEBT 1,080 microg
Number of subjects: 42
Study 16861093 — intervention group
Group type: COMPARATOR
Intervention: OTFC 1,600 microg
Number of subjects: 42
Study 16861093 — intervention group
Group type: EXPERIMENTAL
Intervention: FEBT 270 to 1,300 microg
Number of subjects: 42
Study 14631279 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ropivacaine
Number of subjects: 100
Study 14631279 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine and 2% lidocaine
Number of subjects: 100
Study 11513308 — intervention group
Group type: EXPERIMENTAL
Intervention: slow-release caffeine (300 mg)
Number of subjects: 27
Study 11513308 — intervention group
Group type: EXPERIMENTAL
Intervention: melatonin (5 mg)
Number of subjects: 27
Study 11513308 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27
Study 9756109 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) monotherapy
Number of subjects: 62
Study 7734010 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (20 to 40 mg/d)
Number of subjects: 919
Study 7734010 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 919
Study 3180201 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine 20 mg by slow intravenous injection
Number of subjects: 60
Study 3180201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31894015 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Resiliency Model® (CRM) training, a 3-hour session
Number of subjects: 196
Study 31894015 — intervention group
Group type: COMPARATOR
Intervention: Nutrition education control group
Number of subjects: 196
Study 30850112 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine bathing and mupirocin for MRSA carriers
Number of subjects: 339902
Study 30850112 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 339902
Study 30850112 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine bathing
Number of subjects: 339902
Study 30850112 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin
Number of subjects: 339902
Study 27967328 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic (PG) dosing algorithm
Number of subjects: 140
Study 27967328 — intervention group
Group type: COMPARATOR
Intervention: Previously developed PG algorithm for Greek population
Number of subjects: 140
Study 25845302 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-absorbable 15 × 10 cm folding slit mesh with absorbable tacks (Group 2)
Number of subjects: 146
Study 25845302 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially-absorbable 15 × 10 cm mesh with absorbable tacks (Group 3)
Number of subjects: 146
Study 25845302 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-absorbable 15 × 10 cm anatomical mesh fixed with 2 ml fibrin sealant (Group 4)
Number of subjects: 146
Study 25845302 — intervention group
Group type: COMPARATOR
Intervention: Control group: Non-absorbable 15 × 10 cm anatomical mesh fixed with absorbable tacks
Number of subjects: 146
Study 23978392 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine depletion with α‐methylparatyrosine (AMPT)
Number of subjects: 10
Study 23978392 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 10
Study 20977679 — intervention group
Group type: EXPERIMENTAL
Intervention: FTC/TDF (200/300 mg) + BILR 355/r (150/100 mg)
Number of subjects: 34
Study 20977679 — intervention group
Group type: COMPARATOR
Intervention: BILR 355/r (150/100 mg)
Number of subjects: 34
Study 19875408 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (Ferinject) 200 mg iron i.v. weekly until iron repletion, then monthly until Week 24
Number of subjects: 0
Study 19875408 — intervention group
Group type: COMPARATOR
Intervention: Saline i.v. (placebo)
Number of subjects: 0
Study 17122614 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative endoscopic retrograde cholangiopancreatography (ERCP) with endoscopic sphincterotomy (ES) followed by laparoscopic cholecystectomy (LC)
Number of subjects: 91
Study 17122614 — intervention group
Group type: COMPARATOR
Intervention: Laparoendoscopic rendezvous technique with intraoperative ERCP and ES
Number of subjects: 91
Study 14756638 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of excimer laser treatment and topical tacrolimus 0.1% ointment
Number of subjects: 8
Study 14756638 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Aquaphor)
Number of subjects: 8
Study 11488258 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 551
Study 11488258 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 551
Study 11488258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 551
Study 9350661 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (150 to 225 micrograms)
Number of subjects: 26
Study 9350661 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.154 mmol/liter)
Number of subjects: 26
Study 8404802 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 90
Study 8404802 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training and flexibility exercise
Number of subjects: 90
Study 8404802 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 90
Study 3535811 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg at night
Number of subjects: 62
Study 3535811 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg at night and Naproxen 500 mg twice daily
Number of subjects: 62
Study 3535811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 3535811 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice daily
Number of subjects: 62
Study 28993180 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-tablet regimen of darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg taken once per day for 48 weeks
Number of subjects: 1141
Study 28993180 — intervention group
Group type: COMPARATOR
Intervention: Control regimen of boosted protease inhibitor, emtricitabine, and tenofovir disoproxil fumarate
Number of subjects: 1141
Study 28993180 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-tablet regimen of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide
Number of subjects: 1141
Study 26625418 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbations delivered along the Antero‐Posterior (AP) direction
Number of subjects: 0
Study 26625418 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbations delivered along the Medio‐Lateral (ML) direction
Number of subjects: 0
Study 26625418 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-training session aftereffects
Number of subjects: 0
Study 26625418 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbations of different amplitudes
Number of subjects: 0
Study 25406652 — intervention group
Group type: EXPERIMENTAL
Intervention: CBCT group - mini-implants placed using CBCT data
Number of subjects: 13
Study 25406652 — intervention group
Group type: COMPARATOR
Intervention: RVG group - mini-implants placed using two-dimensional digital radiographs and a custom made guide
Number of subjects: 13
Study 23234029 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect quantitative cardiotocography (qCTG)
Number of subjects: 220
Study 23234029 — intervention group
Group type: COMPARATOR
Intervention: Standard indirect cardiotocography (CTG)
Number of subjects: 220
Study 23234029 — intervention group
Group type: COMPARATOR
Intervention: Standard indirect cardiotocography (CTG) + fetal blood sampling (FBS)
Number of subjects: 220
Study 20955872 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention on inhaler use
Number of subjects: 94
Study 20955872 — intervention group
Group type: COMPARATOR
Intervention: Routine monitoring (Control)
Number of subjects: 94
Study 18031920 — intervention group
Group type: EXPERIMENTAL
Intervention: naltrexone
Number of subjects: 63
Study 18031920 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 63
Study 15676050 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual fentanyl 100 microg
Number of subjects: 9
Study 15676050 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual fentanyl 200 microg
Number of subjects: 9
Study 15676050 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual fentanyl 400 microg
Number of subjects: 9
Study 12593177 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled steroids
Number of subjects: 0
Study 12593177 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled long-acting beta 2-mimetics and steroids
Number of subjects: 0
Study 10511331 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe protein restriction diet (0.30 g/kg/day) supplemented with ketoanalogues (Group A)
Number of subjects: 50
Study 10511331 — intervention group
Group type: COMPARATOR
Intervention: Moderate protein restriction diet (0.65 g/kg/day) (Group B)
Number of subjects: 50
Study 10511331 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between Group A and Group B
Number of subjects: 50
Study 7537921 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet rich in monounsaturated fatty acids (MUFA) for 3 weeks
Number of subjects: 16
Study 7537921 — intervention group
Group type: COMPARATOR
Intervention: Diet rich in polyunsaturated fatty acids (PUFA) for 3 weeks
Number of subjects: 16
Study 2000757 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc-99m teboroxime imaging
Number of subjects: 22
Study 2000757 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT imaging with shorter acquisition time and appropriate filtering
Number of subjects: 22
Study 2000757 — intervention group
Group type: EXPERIMENTAL
Intervention: Planar imaging in upright position
Number of subjects: 22
Study 6240786 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamphenicol (2.5 g perorally)
Number of subjects: 152
Study 6240786 — intervention group
Group type: COMPARATOR
Intervention: Spectinomycin (2.0 g im)
Number of subjects: 152
Study 30862637 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline Concordant Care (GCC)
Number of subjects: 1200
Study 30862637 — intervention group
Group type: COMPARATOR
Intervention: Active Surveillance (AS)
Number of subjects: 1200
Study 29972310 — intervention group
Group type: EXPERIMENTAL
Intervention: Zofenopril plus amlodipine
Number of subjects: 3488
Study 29972310 — intervention group
Group type: COMPARATOR
Intervention: Zofenopril
Number of subjects: 3488
Study 27382811 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline 0.9% (group I)
Number of subjects: 31
Study 27382811 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% (group II)
Number of subjects: 31
Study 24190844 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT)
Number of subjects: 121
Study 24190844 — intervention group
Group type: COMPARATOR
Intervention: Individual adolescent focused therapy (AFT)
Number of subjects: 121
Study 22832068 — intervention group
Group type: EXPERIMENTAL
Intervention: ERP features
Number of subjects: 35
Study 22832068 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency power features
Number of subjects: 35
Study 22832068 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusion model (combination of ERP and power features)
Number of subjects: 35
Study 21175514 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric emergency physician (EP)
Number of subjects: 103
Study 21175514 — intervention group
Group type: COMPARATOR
Intervention: Orthopedic resident
Number of subjects: 103
Study 18684255 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation for long-lasting persistent AF
Number of subjects: 194
Study 18684255 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation for short-lasting persistent AF
Number of subjects: 194
Study 18684255 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation for paroxysmal AF
Number of subjects: 194
Study 18684255 — intervention group
Group type: COMPARATOR
Intervention: Ablation for unsuccessful clinical outcome in long-lasting persistent AF
Number of subjects: 194
Study 15932557 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligasure haemorrhoidectomy
Number of subjects: 30
Study 15932557 — intervention group
Group type: COMPARATOR
Intervention: Conventional diathermy haemorrhoidectomy
Number of subjects: 30
Study 14531932 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 39
Study 14531932 — intervention group
Group type: COMPARATOR
Intervention: Passive range of motion (ROM) exercises
Number of subjects: 39
Study 10320179 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 150 microg in 15 mL of saline (Group Clonidine)
Number of subjects: 45
Study 10320179 — intervention group
Group type: COMPARATOR
Intervention: Saline 15 mL (Group Saline)
Number of subjects: 45
Study 10320179 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 15 mL (Group Bupivacaine)
Number of subjects: 45
Study 8729107 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.2% 18:3n-3
Number of subjects: 27
Study 8729107 — intervention group
Group type: COMPARATOR
Intervention: 0.4% 18:3n-3
Number of subjects: 27
Study 8729107 — intervention group
Group type: COMPARATOR
Intervention: 1.0% 18:3n-3
Number of subjects: 27
Study 1859757 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 120
Study 1859757 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 120
Study 1859757 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone and Propofol combination
Number of subjects: 120
Study 6981173 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous trimethoprim (TMP) 150 mg/m2 and sulfamethoxazole (SMZ) 750 mg/m2 every 8 hr
Number of subjects: 37
Study 6981173 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous trimethoprim (TMP) and sulfamethoxazole (SMZ)
Number of subjects: 37
Study 31526557 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous vitamin C (1,500 mg every 6 hours)
Number of subjects: 50
Study 31526557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30239259 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT infused with motivational interviewing (MI-CBT)
Number of subjects: 85
Study 30239259 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational language
Number of subjects: 85
Study 30239259 — intervention group
Group type: COMPARATOR
Intervention: Self-reported motivation
Number of subjects: 85
Study 28691174 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall school climate
Number of subjects: 500
Study 28691174 — intervention group
Group type: EXPERIMENTAL
Intervention: School climate subscale of engagement
Number of subjects: 500
Study 28691174 — intervention group
Group type: EXPERIMENTAL
Intervention: School climate subscale of environment
Number of subjects: 500
Study 25639601 — intervention group
Group type: EXPERIMENTAL
Intervention: Tweeting about sexism (public tweeters)
Number of subjects: 0
Study 25639601 — intervention group
Group type: COMPARATOR
Intervention: Tweeting about sexism (private tweeters)
Number of subjects: 0
Study 25639601 — intervention group
Group type: COMPARATOR
Intervention: Control groups (three groups)
Number of subjects: 0
Study 23969918 — intervention group
Group type: EXPERIMENTAL
Intervention: One-step self-etching adhesive (OSSE)
Number of subjects: 17
Study 23969918 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-step etch-and-rinse adhesive (TSER)
Number of subjects: 17
Study 23969918 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified ethanol-wet bonding technique (EWBT)
Number of subjects: 17
Study 23969918 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 17
Study 20924813 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent cognitive behavioral group intervention
Number of subjects: 540
Study 19717699 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive therapeutic procedures
Number of subjects: 0
Study 17322149 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (BIBR 1048)
Number of subjects: 287
Study 15145015 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-sewn cervical esophagogastric anastomosis
Number of subjects: 63
Study 15145015 — intervention group
Group type: COMPARATOR
Intervention: Circular stapled cervical esophagogastric anastomosis
Number of subjects: 63
Study 12029403 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone Positioning (PP) for 4 hours once daily until patients could sit in an armchair
Number of subjects: 51
Study 12029403 — intervention group
Group type: COMPARATOR
Intervention: Supine Positioning (SP)
Number of subjects: 51
Study 12029403 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone Positioning (PP)
Number of subjects: 51
Study 9617717 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinemet CR (chronic release formulation of levodopa/carbidopa)
Number of subjects: 40
Study 9617717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7656190 — intervention group
Group type: EXPERIMENTAL
Intervention: tissue plasminogen activator (tPA)
Number of subjects: 35
Study 7656190 — intervention group
Group type: EXPERIMENTAL
Intervention: streptokinase (SK)
Number of subjects: 35
Study 7656190 — intervention group
Group type: COMPARATOR
Intervention: ST response
Number of subjects: 35
Study 7656190 — intervention group
Group type: COMPARATOR
Intervention: ST response before 120 mins
Number of subjects: 35
Study 7656190 — intervention group
Group type: COMPARATOR
Intervention: ST trends
Number of subjects: 35
Study 1779440 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous acupuncture (2 to 5 ml of 20% glucose solution injected into Ho‐Ku (LI 4) and Yang‐Ling‐Chuan (GB 34))
Number of subjects: 12
Study 1779440 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched controls)
Number of subjects: 12
Study 7249557 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking a cigarette
Number of subjects: 23
Study 7249557 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent inhalations of charcoal
Number of subjects: 23
Study 7249557 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal and laryngeal anaesthesia with lignocaine
Number of subjects: 23
Study 7249557 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtration of particulate matter from cigarette smoke
Number of subjects: 23
Study 30592371 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVR) 1.5 mg twice daily starting on day 8
Number of subjects: 140
Study 30592371 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVR)
Number of subjects: 140
Study 30592371 — intervention group
Group type: COMPARATOR
Intervention: Control (Tacrolimus - TAC)
Number of subjects: 140
Study 28585903 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg twice daily for 30 days
Number of subjects: 300
Study 28585903 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 81 mg daily for 30 days
Number of subjects: 300
Study 26206864 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline plus higher-intensity, progressive aerobic exercise (S+PAE)
Number of subjects: 121
Study 26206864 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline plus lower-intensity, non-progressive exercise (S+NPE)
Number of subjects: 121
Study 26206864 — intervention group
Group type: COMPARATOR
Intervention: Sertraline alone
Number of subjects: 121
Study 24447007 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Risers 'Skills for Success' Conduct Problems Prevention Program (ER) for 3 intensive years plus 2 booster years
Number of subjects: 245
Study 24447007 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 245
Study 21926383 — intervention group
Group type: EXPERIMENTAL
Intervention: Lace-up ankle braces
Number of subjects: 2081
Study 21926383 — intervention group
Group type: COMPARATOR
Intervention: Control group (no braces)
Number of subjects: 2081